Give breast cancer patients flexible working conditions, says MEP
Cancer patients have a great deal to contribute to the workplace and should be supported though flexible working policies, says an MEP who is herself a cancer survivor.
Photo credit: PA
Belgian Alde group MEP Lieve Wierinck has thrown her weight behind a campaign to make it easier for people with advanced breast cancer to return to work and be supported though flexible working arrangements.
Hosting an event at the European Parliament which sought to highlight to policy makers the financial burden of breast cancer, Wierinck spoke her of her own personal “battles” with cancer.
She said she was a deputy in the Flemish parliament at the time of her diagnosis. She was successfully treated and eventually went back to work.
- Women working night shifts have 30 percent higher risk of developing breast cancer
- A ten-year success story on tackling rare cancers
- Cancer is the leading cause of work-related deaths in the EU, explains Christa Sedlatschek.
- Work-related cancers: Growing demand for urgent action
- Alojz Peterle: Towards a Europe free of cancers
"I was very happy to go to work because that was part of the rehabilitation process, but for many it is not so easy and returning to work is a real problem because of the inflexibility of their employers. This has to change because cancer patients still have an awful lot to contribute to the workplace," Wierinck said.
Many are unable to return to work because of a lack of understanding about their disease or through direct or indirect discrimination, she added.
Parliament is currently looking at proposals for a new directive on work-life balance which will include a provision for work leave for people caring for children or seriously ill relatives.
Campaigners are asking MEPs to look at the working rights of cancer patients as well.
"I was very happy to go to work because that was part of the rehabilitation process, but for many it is not so easy and returning to work is a real problem because of the inflexibility of their employers" Lieve Wierinck
MASSIVE LOSS OF PRODUCTIVITY
Dr Fatima Cardoso of the Champalimaud Clinical Centre in Lisbon and chair of the campaign group, ABC Global Alliance, said: "Most people with breast cancer are in the most economically-productive years of their lives in their 40s, 50s and 60s."
"Not being able to work is bad for them, not only financially, but also emotionally and psychologically, and it is also bad for society. There are many studies now that show the indirect costs of cancer, because of lack of productivity, are actually bigger than the direct costs. If these people can continue to work and be productive, it will be much better for society as a whole."
Breast cancer is the most frequently-diagnosed cancer worldwide, affecting mainly women but some men too. Over two million new cases of breast cancer will be diagnosed in 2018 and nearly 630,000 people will die from it, almost all from advanced or metastatic disease - cancer that has spread to other parts of the body.
Wierinck’s event heard that there are around 6.8 million people who are either breast cancer survivors or currently living with advanced disease - many of whom are capable of, and want to, work.
"Making it difficult or impossible for these people to continue working is resulting in a colossal loss in economic productivity to society," said Dr Cardoso.
Barbara Wilson, who heads the social enterprise Working with Cancer in the UK, which helps people affected by cancer return to work, told the meeting: "Even for people who are living with the long-term side effects of their treatment, it’s perfectly possible for them to continue to work if there are proper strategies in place to support them."
Wilson added, "This is not about making people return to work, but if someone wants to return, it can, in most cases be managed successfully."
"In order to achieve this, employers need to understand cancer, they need to communicate effectively with employees affected by cancer, and they need to implement flexible working policies during and after treatment, including providing individualised support for those that need it in the form of one-to-one coaching."
"Too often employers assume either that you should not work and encourage you to leave, or they think that a few weeks after treatment, you’ll be fine and then wonder why you are not ‘back to normal’ as quickly as expected. Neither of these assumptions is helpful; even terminally ill people can sometimes work, nearly up to the time they die, depending on their cancer and the type of work they do."
MORE UNDERSTANDING NEEDED
Another speaker, Karen Benn, deputy CEO of Europa Donna, called for all employers to ensure they have training to improve their understanding of cancer and how they communicate with their employees, and they should also have policies that support flexible working.
In addition, governments across Europe and, indeed, worldwide, should put in place legislation to make it unlawful for employers to discriminate against people with cancer.
"At the moment some countries have such legislation, while many others don’t. Workplace adjustments often cost tiny amounts compared with the cost of losing a good employee and the cost of recruiting new people."
Benn added: "It is vital that people living with advanced breast cancer are not discriminated against in the workplace and policy needs to reflect this."
Professor Richard Sullivan, a surgeon and global cancer policy expert at the Institute of Cancer Policy, King’s College London, said not only were costs incurred by patients, employers and society through loss of productivity when people living with breast cancer found it difficult or impossible to work, but also because of the way cancer treatment and care is managed and funded. He challenged national governments to address the current disconnection between the costs of cancer care and patient outcomes.
"This is a really serious problem. We have data that show that the cost of cancer care versus the outcomes for individual patients are completely unconnected. You have countries in Europe that are spending huge amounts on clinical care but are seeing virtually no improvement in outcomes. For instance, Greece is spending a substantial amount on breast cancer treatment - €34,500 per new case per year - but has seen only minimal improvement in breast cancer outcomes, whereas other countries have a reduction in the number of deaths of around 20-30 percent. This all comes down to the governance of cancer care - most countries are just not doing this properly and are paying a lot of money for rubbish care."
Sullivan told the meeting that this was a complex problem that had difficult and uncomfortable solutions.
"A lot of countries across Europe are losing the battle in delivering affordable, equitable, high-quality care. Governments need to have ruthless pricing and reimbursement control through a transparent mechanism that relates cost to patient outcomes, and that also relates to what is happening in the real world, not just in super centres of clinical excellence."
"In addition, there needs to be proper governance of clinical care and pathways, so that all patients receive the correct care at the right stage on their cancer journey," he added.
Early detection and integrated healthcare are key to tackling brain disorders, argues David Nutt.
The Paediatric Cancer network, ERN PaedCan is helping to break down barriers to effective cross-border healthcare, writes Ruth Ladenstein
EU’s policymakers need to recognise the scale and threat of Alzheimer’s and Parkinson’s disease, argues Colin Mackay